518 related articles for article (PubMed ID: 27272171)
1. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
[TBL] [Abstract][Full Text] [Related]
2. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Genovese MC; Smolen JS; Weinblatt ME; Burmester GR; Meerwein S; Camp HS; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S
Arthritis Rheumatol; 2016 Dec; 68(12):2857-2866. PubMed ID: 27390150
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Mohamed MF; Zeng J; Marroum PJ; Song IH; Othman AA
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):208-216. PubMed ID: 29688617
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Klünder B; Mohamed MF; Othman AA
Clin Pharmacokinet; 2018 Aug; 57(8):977-988. PubMed ID: 29076110
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
Khatri A; Goss S; Jiang P; Mansikka H; Othman AA
Clin Pharmacokinet; 2018 May; 57(5):613-623. PubMed ID: 28744796
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants.
Chen K; Guan X; Yang Z; Zhou Y; Liu Z; Deng X; Liu D; Hu P; Chen R
Front Immunol; 2023; 14():1127935. PubMed ID: 37077916
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI; Shojaee N; Singh RSP; Li C; Gilbert SA; Manukyan Z; Kilty I
Arthritis Res Ther; 2019 Dec; 21(1):269. PubMed ID: 31805989
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
15. Upadacitinib for the treatment of rheumatoid arthritis.
Serhal L; Edwards CJ
Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
Khatri A; Othman AA
J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Mohamed MF; Gopalakrishnan S; Teixeira HD; Othman AA
J Clin Pharmacol; 2021 May; 61(5):628-635. PubMed ID: 33156550
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
20. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Mohamed MF; Beck D; Camp HS; Othman AA
J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]